{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:28:23Z","timestamp":1788546503967,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"crossref","award":["20161406"],"award-info":[{"award-number":["20161406"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270166"],"award-info":[{"award-number":["82270166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Gilteritinib is the only drug approved as monotherapy for acute myeloid leukemia (AML) patients harboring FMS-like tyrosine kinase 3 internal tandem duplication (\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD) mutation throughout the world. However, drug resistance inevitably develops in clinical. Sitravatinib is a multi-kinase inhibitor under evaluation in clinical trials of various solid tumors. In this study, we explored the antitumor activity of sitravatinib against\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD and clinically-relevant drug resistance in\n                      <jats:italic>FLT3<\/jats:italic>\n                      mutant AML.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Growth inhibitory assays were performed in AML cell lines and BaF3 cells expressing various\n                      <jats:italic>FLT3<\/jats:italic>\n                      mutants to evaluate the antitumor activity of sitravatinib in vitro. Immunoblotting was used to examine the activity of FLT3 and its downstream pathways. Molecular docking was performed to predict the binding sites of FLT3 to sitravatinib. The survival benefit of sitravatinib in vivo was assessed in MOLM13 xenograft mouse models and mouse models of transformed BaF3 cells harboring different\n                      <jats:italic>FLT3<\/jats:italic>\n                      mutants. Primary patient samples and a patient-derived xenograft (PDX) model were also used to determine the efficacy of sitravatinib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sitravatinib inhibited cell proliferation, induced cell cycle arrest and apoptosis in\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD AML cell lines. In vivo studies showed that sitravatinib exhibited a better therapeutic effect than gilteritinib in MOLM13 xenograft model and BaF3-\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD model. Unlike gilteritinib, the predicted binding sites of sitravatinib to FLT3 did not include F691 residue. Sitravatinib displayed a potent inhibitory effect on\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD-F691L mutation which conferred resistance to gilteritinib and all other FLT3 inhibitors available, both in vitro and in vivo. Compared with gilteritinib, sitravatinib retained effective activity against\n                      <jats:italic>FLT3<\/jats:italic>\n                      mutation in the presence of cytokines through the more potent and steady inhibition of p-ERK and p-AKT. Furthermore, patient blasts harboring\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD were more sensitive to sitravatinib than to gilteritinib in vitro and in the PDX model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our study reveals the potential therapeutic role of sitravatinib in\n                      <jats:italic>FLT3<\/jats:italic>\n                      mutant AML and provides an alternative inhibitor for the treatment of AML patients who are resistant to current FLT3 inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40364-022-00447-4","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T22:03:29Z","timestamp":1674511409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia"],"prefix":"10.1186","volume":"11","author":[{"given":"Yvyin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"issue":"23","key":"447_CR1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"22","key":"447_CR2","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"3","key":"447_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089560","volume":"9","author":"H Janke","year":"2014","unstructured":"Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, et al. Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia. PLoS ONE. 2014;9(3): e89560.","journal-title":"PLoS ONE"},{"issue":"1","key":"447_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2004-07-2942","volume":"106","author":"C Choudhary","year":"2005","unstructured":"Choudhary C, Schw\u00e4ble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood. 2005;106(1):265\u201373.","journal-title":"Blood"},{"issue":"12","key":"447_CR5","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","volume":"99","author":"C Thiede","year":"2002","unstructured":"Thiede C, Steudel C, Mohr B, Schaich M, Sch\u00e4kel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326\u201335.","journal-title":"Blood"},{"issue":"1","key":"447_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41375-021-01323-0","volume":"36","author":"FG R\u00fccker","year":"2022","unstructured":"R\u00fccker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, et al. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. 2022;36(1):90\u20139.","journal-title":"Leukemia"},{"issue":"5","key":"447_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3324\/haematol.2010.034074","volume":"96","author":"K Wagner","year":"2011","unstructured":"Wagner K, Damm F, Thol F, G\u00f6hring G, G\u00f6rlich K, Heuser M, et al. FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. Haematologica. 2011;96(5):681\u20136.","journal-title":"Haematologica"},{"issue":"2","key":"447_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299\u2013312.","journal-title":"Leukemia"},{"issue":"6","key":"447_CR9","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","volume":"64","author":"Z Wang","year":"2021","unstructured":"Wang Z, Cai J, Cheng J, Yang W, Zhu Y, Li H, et al. FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. J Med Chem. 2021;64(6):2878\u2013900.","journal-title":"J Med Chem"},{"issue":"1","key":"447_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","volume":"13","author":"MT Gebru","year":"2020","unstructured":"Gebru MT, Wang HG. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):155.","journal-title":"J Hematol Oncol"},{"issue":"18","key":"447_CR11","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med"},{"key":"447_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100905","volume":"52","author":"JC Zhao","year":"2022","unstructured":"Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52: 100905.","journal-title":"Blood Rev"},{"issue":"7","key":"447_CR13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/bloodadvances.2018029850","volume":"3","author":"PJ Sung","year":"2019","unstructured":"Sung PJ, Sugita M, Koblish H, Perl AE, Carroll M. Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. Blood Adv. 2019;3(7):1061\u201372.","journal-title":"Blood Adv"},{"issue":"4","key":"447_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","volume":"31","author":"G Ghiaur","year":"2017","unstructured":"Ghiaur G, Levis M. Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment. Hematol Oncol Clin North Am. 2017;31(4):681\u201392.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"447_CR15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","volume":"39","author":"SK Joshi","year":"2021","unstructured":"Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, et al. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell. 2021;39(7):999-1014.e8.","journal-title":"Cancer Cell"},{"issue":"2","key":"447_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","volume":"2","author":"AS Alotaibi","year":"2021","unstructured":"Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, et al. Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors. Blood Cancer Discov. 2021;2(2):125\u201334.","journal-title":"Blood Cancer Discov"},{"issue":"7397","key":"447_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature11016","volume":"485","author":"CC Smith","year":"2012","unstructured":"Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260\u20133.","journal-title":"Nature"},{"issue":"8","key":"447_CR18","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","volume":"9","author":"CM McMahon","year":"2019","unstructured":"McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette J, Eastburn DJ, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to Selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9(8):1050\u201363.","journal-title":"Cancer Discov"},{"issue":"7","key":"447_CR19","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","volume":"6","author":"CC Smith","year":"2022","unstructured":"Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144\u201355.","journal-title":"Blood Adv"},{"issue":"8","key":"447_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/biomedicines8080245","volume":"8","author":"M Eguchi","year":"2020","unstructured":"Eguchi M, Minami Y, Kuzume A, Chi S. Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia. Biomedicines. 2020;8(8):245.","journal-title":"Biomedicines"},{"issue":"4","key":"447_CR21","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.18632\/oncotarget.6547","volume":"7","author":"PP Patwardhan","year":"2016","unstructured":"Patwardhan PP, Ivy KS, Musi E, de Stanchina E, Schwartz GK. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget. 2016;7(4):4093\u2013109.","journal-title":"Oncotarget"},{"issue":"21","key":"447_CR22","doi-asserted-by":"publisher","first-page":"e124184","DOI":"10.1172\/jci.insight.124184","volume":"3","author":"W Du","year":"2018","unstructured":"Du W, Huang H, Sorrelle N, Brekken RA. Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight. 2018;3(21):e124184.","journal-title":"JCI Insight"},{"issue":"641","key":"447_CR23","doi-asserted-by":"publisher","first-page":"eabm6420","DOI":"10.1126\/scitranslmed.abm6420","volume":"14","author":"P Msaouel","year":"2022","unstructured":"Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, et al. A phase 1\u20132 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022;14(641):eabm6420.","journal-title":"Sci Transl Med"},{"issue":"8","key":"447_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220101","volume":"14","author":"M Dolan","year":"2019","unstructured":"Dolan M, Mastri M, Tracz A, Christensen JG, Chatta G, Ebos J. Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. PLoS ONE. 2019;14(8): e0220101.","journal-title":"PLoS ONE"},{"key":"447_CR25","doi-asserted-by":"crossref","unstructured":"Oliva M, Chepeha D, Araujo DV, Diaz-Mejia JJ, Olson P, Prawira A, et al. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. J Immunother Cancer. 2021;9(10):e003476.","DOI":"10.1136\/jitc-2021-003476"},{"issue":"22","key":"447_CR26","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1182\/blood-2013-07-513044","volume":"122","author":"EI Zimmerman","year":"2013","unstructured":"Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood. 2013;122(22):3607\u201315.","journal-title":"Blood"},{"issue":"5","key":"447_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","volume":"35","author":"M Mori","year":"2017","unstructured":"Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R, et al. Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017;35(5):556\u201365.","journal-title":"Invest New Drugs"},{"issue":"9","key":"447_CR28","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/nprot.2014.138","volume":"9","author":"R Jafari","year":"2014","unstructured":"Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundb\u00e4ck T, Nordlund P, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014;9(9):2100\u201322.","journal-title":"Nat Protoc"},{"issue":"21","key":"447_CR29","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-20-3114","volume":"27","author":"PY Dumas","year":"2021","unstructured":"Dumas PY, Villacreces A, Guitart AV, El-Habhab A, Massara L, Mansier O, et al. Dual inhibition of FLT3 and AXL by gilteritinib overcomes hematopoietic niche-driven resistance mechanisms in FLT3-ITD acute myeloid leukemia. Clin Cancer Res. 2021;27(21):6012\u201325.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"447_CR30","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1182\/blood.2019001282","volume":"134","author":"X He","year":"2019","unstructured":"He X, Zhu Y, Lin YC, Li M, Du J, Dong H, et al. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD(+) acute myeloid leukemia. Blood. 2019;134(6):548\u201360.","journal-title":"Blood"},{"issue":"14","key":"447_CR31","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","volume":"114","author":"PP Zarrinkar","year":"2009","unstructured":"Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984\u201392.","journal-title":"Blood"},{"issue":"5","key":"447_CR32","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s10637-022-01274-y","volume":"40","author":"T Bauer","year":"2022","unstructured":"Bauer T, Cho BC, Heist R, Bazhenova L, Werner T, Goel S, et al. First-in-human phase 1\/1b study to evaluate sitravatinib in patients with advanced solid tumors. Invest New Drugs. 2022;40(5):990\u20131000.","journal-title":"Invest New Drugs"},{"issue":"8","key":"447_CR33","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","volume":"18","author":"AE Perl","year":"2017","unstructured":"Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1\u20132 study. Lancet Oncol. 2017;18(8):1061\u201375.","journal-title":"Lancet Oncol"},{"issue":"3","key":"447_CR34","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","volume":"34","author":"AI Antar","year":"2020","unstructured":"Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020;34(3):682\u201396.","journal-title":"Leukemia"},{"issue":"3","key":"447_CR35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1182\/bloodadvances.2019000919","volume":"4","author":"TC Tarver","year":"2020","unstructured":"Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, et al. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood Adv. 2020;4(3):514\u201324.","journal-title":"Blood Adv"},{"issue":"4","key":"447_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121177","volume":"10","author":"JA Zorn","year":"2015","unstructured":"Zorn JA, Wang Q, Fujimura E, Barros T, Kuriyan J. Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220). PLoS ONE. 2015;10(4): e0121177.","journal-title":"PLoS ONE"},{"issue":"22","key":"447_CR37","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","volume":"25","author":"J Ma","year":"2019","unstructured":"Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, et al. Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia. Clin Cancer Res. 2019;25(22):6815\u201326.","journal-title":"Clin Cancer Res"},{"key":"447_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2026","volume":"375","author":"LF Newell","year":"2021","unstructured":"Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375: n2026.","journal-title":"BMJ"},{"issue":"4","key":"447_CR39","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"5","key":"447_CR40","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454\u201364.","journal-title":"N Engl J Med"},{"issue":"7","key":"447_CR41","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984\u201397.","journal-title":"Lancet Oncol"},{"issue":"7","key":"447_CR42","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","volume":"19","author":"J Cortes","year":"2018","unstructured":"Cortes J, Perl AE, D\u00f6hner H, Kantarjian H, Martinelli G, Kovacsovics T, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889\u2013903.","journal-title":"Lancet Oncol"},{"issue":"14","key":"447_CR43","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/cncr.28705","volume":"120","author":"Y Alvarado","year":"2014","unstructured":"Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, et al. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014;120(14):2142\u20139.","journal-title":"Cancer"},{"issue":"7","key":"447_CR44","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1158\/0008-5472.CAN-08-2923","volume":"69","author":"N von Bubnoff","year":"2009","unstructured":"von Bubnoff N, Engh RA, Aberg E, S\u00e4nger J, Peschel C, Duyster J. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res. 2009;69(7):3032\u201341.","journal-title":"Cancer Res"},{"issue":"11","key":"447_CR45","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3390\/cells9112493","volume":"9","author":"S Scholl","year":"2020","unstructured":"Scholl S, Fleischmann M, Schnetzke U, Heidel FH. Molecular mechanisms of resistance to FLT3 inhibitors in acute myeloid leukemia: ongoing challenges and future treatments. Cells. 2020;9(11):2493.","journal-title":"Cells"},{"issue":"2","key":"447_CR46","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111(2):312\u201322.","journal-title":"Cancer Sci"},{"issue":"4","key":"447_CR47","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/ijms21041537","volume":"21","author":"S Lam","year":"2020","unstructured":"Lam S, Leung A. Overcoming resistance to FLT3 inhibitors in the Treatment of FLT3-mutated AML. Int J Mol Sci. 2020;21(4):1537.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"447_CR48","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","volume":"117","author":"T Sato","year":"2011","unstructured":"Sato T, Yang X, Knapper S, White P, Smith BD, Galkin S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011;117(12):3286\u201393.","journal-title":"Blood"},{"issue":"22","key":"447_CR49","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","volume":"76","author":"E Traer","year":"2016","unstructured":"Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, et al. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Res. 2016;76(22):6471\u201382.","journal-title":"Cancer Res"},{"issue":"11","key":"447_CR50","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1182\/blood-2012-07-444018","volume":"121","author":"IK Park","year":"2013","unstructured":"Park IK, Mishra A, Chandler J, Whitman SP, Marcucci G, Caligiuri MA. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood. 2013;121(11):2064\u201373.","journal-title":"Blood"},{"issue":"12","key":"447_CR51","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/leu.2015.147","volume":"29","author":"IK Park","year":"2015","unstructured":"Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, et al. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. 2015;29(12):2382\u20139.","journal-title":"Leukemia"},{"issue":"10","key":"447_CR52","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3324\/haematol.2018.205385","volume":"104","author":"PY Dumas","year":"2019","unstructured":"Dumas PY, Naudin C, Martin-Lanner\u00e9e S, Izac B, Casetti L, Mansier O, et al. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL. Haematologica. 2019;104(10):2017\u201327.","journal-title":"Haematologica"},{"issue":"7","key":"447_CR53","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/cac2.12040","volume":"40","author":"Y Yang","year":"2020","unstructured":"Yang Y, Ji N, Cai CY, Wang JQ, Lei ZN, Teng QX, et al. Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor. Cancer Commun (Lond). 2020;40(7):285\u2013300.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"447_CR54","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/cancers12010195","volume":"12","author":"CP Wu","year":"2020","unstructured":"Wu CP, Hsiao SH, Huang YH, Hung LC, Yu YJ, Chang YT, et al. Sitravatinib sensitizes ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Cancers (Basel). 2020;12(1):195.","journal-title":"Cancers (Basel)"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-022-00447-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-022-00447-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-022-00447-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T11:04:22Z","timestamp":1675335862000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-022-00447-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1186\/s40364-022-00447-4","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"30 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Ruijin Hospital, Shanghai Jiaotong University School of Medicine in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}